Novartis to Divest Portions of Sandoz US to Aurobindo
Novartis (NVS) announced today, September 6, that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA for $0.9 billion in cash and $0.1 billion in potential earn-outs. The select portions include the Sandoz US dermatology business and the generic US oral solids business. The deal includes ~300 products and additional development programs that will be transferred from Sandoz’s US portfolio to Aurobindo.